Hologic (FRA:HO1) EBIT: €667 Mil (TTM As of Dec. 2025)


FRA:HO1 Hologic Inc FRA:HO1
57 GF Score
Price €65.00
GF Value €70.17
! 4 Warning Signs
View Full Analysis

What is Hologic EBIT?

Hologic FRA:HO1 57 EBIT is €667 Mil as of Dec. 2025. GuruFocus rates FRA:HO1 with a GF Score™ of 57/100 and a GF Value™ of €70.17. The stock has 4 warning signs investors should review.

Hologic's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was €220 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €667 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hologic's annualized ROC % for the quarter that ended in Dec. 2025 was 12.13%. Hologic's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 90.38%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hologic's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 4.50%.


Hologic  (FRA:HO1) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hologic's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=822.916 * ( 1 - 22.03% )/( (5420.68 + 5162.345)/ 2 )
=641.6276052/5291.5125
=12.13 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7680.695 - 383.315 - ( 1876.7 - max(0, 832.574 - 3125.221+1876.7))
=5420.68

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7840.318 - 658.519 - ( 2019.454 - max(0, 812.41 - 3282.264+2019.454))
=5162.345

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Hologic's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=878.936/( ( (556.952 + max(444.404, 0)) + (485.328 + max(458.342, 0)) )/ 2 )
=878.936/( ( 1001.356 + 943.67 )/ 2 )
=878.936/972.513
=90.38 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(511.882 + 578.849 + 157.79) - (383.315 + 170.144 + 250.658)
=444.404

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(498.907 + 587.979 + 175.924) - (658.519 + 145.949 + -1.1368683772162E-13)
=458.342

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hologic's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=667.032/14838.572
=4.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hologic EBIT Related Terms


Hologic EBIT Historical Data

* Premium members only.

The historical data trend for Hologic's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hologic EBIT Chart

Hologic Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,086.50 1,700.13 737.61 889.47 680.15

Hologic Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 265.49 0.56 228.80 217.94 219.73

FRA:HO1 vs WST, COO, ALGN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Hologic's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hologic EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Hologic's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hologic's EV-to-EBIT falls into.


FRA:HO1
57GF Score
Hologic Inc FRA:HO1
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hologic EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €667 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €667 Mil mean?
Hologic (FRA:HO1) has a EBIT of €667 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hologic.
Is Hologic's EBIT too high?
Hologic's current EBIT is €667 Mil. Overall, Hologic has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Hologic's EBIT compare to WST and COO?
Hologic's EBIT of €667 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hologic. Hologic's current EBIT is €667 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hologic stock overvalued right now?
Hologic (FRA:HO1) has a current EBIT of €667 Mil. The stock's GF Value™ is €70.17, compared to a current price of €65.00 — trading 7.4% below its estimated fair value. The current EBIT is €667 Mil. Hologic's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Hologic (FRA:HO1), the current EBIT is €667 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hologic (FRA:HO1) Overvalued in 2026?

Based on GuruFocus' analysis, Hologic stock appears to be undervalued. The current stock price of €65.00 is trading 7.4% below its estimated GF Value™ of €70.17.

Key valuation signals for FRA:HO1:

  • EBIT: €667 Mil
  • GF Value™: €70.17 vs. price of €65.00 (7.4% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the FRA:HO1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hologic Business Description

Address 250 Campus Drive, Marlborough, MA, USA, 01752
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
57GF Score

Get the complete analysis for FRA:HO1

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.00
Price
€70.17
GF Value